Friday, March 14, 2025 10:30:43 AM
Series J Preferred Stock? Are these getting reverse split too?
Series J Preferred Stock is not entitled to vote, on an as-converted basis and in the aggregate with respect to any shares of Common Stock and preferred stock of the Company beneficially owned by such holder and any Affiliates or Attribution Parties (as such terms are defined in the Certificate of Designation of Series J Preferred Stock) of such holder, more than 9.99% of the Company’s outstanding shares of Common Stock as of the applicable record date.
The final results for the votes regarding each proposal are set forth below.
1.
Proposal to approve an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share, at a ratio of not less than 1-for-15 and not greater than 1-for-40, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before March 13, 2026 without further approval or authorization of the Company’s stockholders, was approved by the stockholders by the following vote:
Series J Preferred Stock is not entitled to vote, on an as-converted basis and in the aggregate with respect to any shares of Common Stock and preferred stock of the Company beneficially owned by such holder and any Affiliates or Attribution Parties (as such terms are defined in the Certificate of Designation of Series J Preferred Stock) of such holder, more than 9.99% of the Company’s outstanding shares of Common Stock as of the applicable record date.
The final results for the votes regarding each proposal are set forth below.
1.
Proposal to approve an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share, at a ratio of not less than 1-for-15 and not greater than 1-for-40, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before March 13, 2026 without further approval or authorization of the Company’s stockholders, was approved by the stockholders by the following vote:
Recent JAGX News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/29/2026 09:23:41 PM
- Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders • ACCESS Newswire • 05/28/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 01:10:06 PM
- Jaguar Health Compliant with Nasdaq Bid Price Rule • ACCESS Newswire • 05/27/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 09:22:44 PM
- Jaguar Health Reports First Quarter 2026 Financials • ACCESS Newswire • 05/20/2026 08:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:36:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2026 08:06:56 PM
- Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference • ACCESS Newswire • 05/20/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/19/2026 09:07:21 PM
- Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer • ACCESS Newswire • 05/19/2026 01:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/18/2026 07:06:14 PM
- Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule • ACCESS Newswire • 05/08/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 06:59:08 PM
- Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) • ACCESS Newswire • 05/06/2026 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2026 12:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 09:09:41 PM
- Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 12:00:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 01:57:16 PM
- Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs • ACCESS Newswire • 04/29/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 01:10:06 PM
- Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split • ACCESS Newswire • 04/27/2026 01:00:00 PM
- Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) • ACCESS Newswire • 04/24/2026 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/21/2026 12:22:02 PM
